Valeant submits retigabine applications

Valeant Pharmaceuticals International (NYSE:VRX) submitted an NDA in the U.S. and an MAA in Europe for retigabine as an adjunctive therapy for partial-onset seizures in adults with epilepsy. Valeant a...